• Genetic Testing Throughout Disease Course Critical in Lung Cancer
    on September 23, 2019 at 9:40 pm

    Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.

  • Genomics Are Key to Unlocking Breast Cancer Biology
    on September 23, 2019 at 7:21 pm

    Paul Kelly Marcom, MD, discusses the role of genomic testing in breast cancer.

  • NYU Langone’s Perlmutter Cancer Center Buzzing With Breast Cancer Research
    on September 23, 2019 at 6:35 pm

    Thought leaders from NYU Langone’s Perlmutter Cancer Center highlight the latest groundbreaking research being conducted at their institution.

  • Brentuximab Vedotin and Nivolumab Explored in Frontline Hodgkin Lymphoma Regimen
    on September 23, 2019 at 5:16 pm

    The addition of the antibody-drug conjugate brentuximab vedotin and the PD-1 inhibitor nivolumab to chemotherapy in patients with stage I/II Hodgkin lymphoma is under investigation in an ongoing phase II trial (NCT03233347).

  • CAR T Cells Could Revolutionize RCC Treatment
    on September 23, 2019 at 4:54 pm

    Wayne A. Marasco, MD, PhD, discusses the intricacy of engineering CAR T cells and the early data he has observed with CAR T-cell therapy in renal cell carcinoma.&nbs

  • Larotrectinib Approved in Europe for NTRK+ Tumors
    on September 23, 2019 at 4:26 pm

    The European Commission has approved larotrectinib for the treatment of certain adult and pediatric patients with solid tumors who have an NTRK gene fusion without a known acquired resistance mutation.

  • FDA Approves CRC Screening Test for Younger, At-Risk Individuals
    on September 23, 2019 at 1:44 pm

    The FDA has expanded the approval of the noninvasive colorectal cancer (CRC) screening test Cologuard to include eligible at-risk individuals ≥45 years.

  • Immune Checkpoint Inhibitors Correlate With Specific Neurologic Events
    on September 23, 2019 at 1:41 pm

    Use of immune checkpoint inhibitors was clearly associated with higher incidences of specific neurologic toxicities in a broad-based retrospective pharmacovigilance study, and clinicians need to monitor for these immune-related adverse events when using these agents.

  • Small Subgroups May Hold Big Clinical Clues in Oncology
    on September 23, 2019 at 11:11 am

    With the revolution in our understanding of cancer’s basic molecular biology, it is increasingly evident that subgroups of cancer originating from specific regions of the body have unique natural histories and respond to very different therapeutics. For example, the importance of BRCA mutations, which define a subset of ovarian cancers impressively sensitive to PARP inhibitors, has striking altered the management of this group of gynecologic malignancies.

  • The FDA Could Help Address Financial Toxicity During the Approval Process
    on September 21, 2019 at 10:00 am

    Given the widespread financial impact the high cost of cancer drugs has on the healthcare system, it may be time for the FDA to take a broader approach when reviewing oncology drug applications. By also examining the cost of the drug, the FDA could shine a light on escalating drug costs and play a leadership role in creating new programs and initiatives that help patients pay for promising new therapies.

  • FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia
    by admin on September 20, 2019 at 1:52 pm

    This post was originally published on this site Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The designation is given to therapies that show potential to treat serious health conditions, and […] The post FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia […]

  • FDA Grants New Indication for Erleada for mCSPC
    on September 19, 2019 at 2:30 pm

    The FDA gave the nod to Janssen’s Erleada for patients with metastatic castration-sensitive prostate cancer.